Aktis Oncology, Inc. (AKTS) shareholders
Close on Nov 17, 2026Market cap $907.15MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ansbert Gadicke Joint filing with Luke Evnin (9.50%), Oncology Impact Private Investment Fund 2, L.P. (9.10%) and 5 more | 10,260,064 | 19.30% | 13D (active) | Jan 12, 2026 |
| Eli Lilly and Company | 6,344,114 | 11.90% | 13D (active) | Jan 12, 2026 |
| Helen Kim Joint filing with VV Manager II LLC (10.90%), Vida Ventures II, LLC (10.60%) | 5,831,315 | 10.90% | 13D (active) | Jan 12, 2026 |
| Oleg Nodelman Joint filing with EcoR1 Capital, LLC (9.10%), EcoR1 Capital Fund Qualified, L.P. (8.20%) | 4,862,335 | 9.10% | 13D (active) | Jan 12, 2026 |
| Blue Owl Capital Holdings LP | 3,161,348 | 5.92% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AKTS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Mpm Bioimpact LLC | 4,835,872 | 8.69% | $155.86M | – | 9.50% |
| EcoR1 Capital, LLC | 4,824,469 | 8.67% | $155.49M | – | 7.56% |
| Blue Owl Capital Holdings LP | 3,070,219 | 5.52% | $98.95M | −91,129 | 14.89% |
| BlackRock, Inc. | 2,278,358 | 4.10% | $73.43M | +166,231 | 0.00% |
| T. Rowe Price Investment Management, Inc. | 2,051,447 | 3.69% | $66.12M | −72,365 | 0.04% |
| Wellington Management Group Llp | 1,966,244 | 3.54% | $63.37M | −350,800 | 0.01% |
| Rtw Investments, LP | 1,592,043 | 2.86% | $51.31M | – | 0.44% |
| Ra Capital Management, L.P. | 1,314,405 | 2.36% | $42.36M | −188,679 | 0.37% |
| Jupiter Topco LLC | 1,314,267 | 2.36% | $42.36M | New | 0.02% |
| Baker Bros. Advisors LP | 996,351 | 1.79% | $32.11M | – | 0.16% |
| Octagon Capital Advisors LP | 960,847 | 1.73% | $30.97M | – | 2.78% |
| Merck & Co., Inc. | 952,844 | 1.71% | $30.71M | – | 5.83% |
| Vanguard Capital Management LLC | 817,075 | 1.47% | $26.33M | −16,838 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 763,499 | 1.37% | $24.61M | −800,697 | 0.00% |
| TCG Crossover Management, LLC | 696,560 | 1.25% | $22.45M | New | 0.54% |
| Geode Capital Management, LLC | 520,737 | 0.94% | $16.79M | +28,801 | 0.00% |
| Eventide Asset Management, LLC | 507,000 | 0.91% | $16.34M | – | 0.22% |
| Avidity Partners Management LP | 484,200 | 0.87% | $15.61M | −452,932 | 2.50% |
| State Street Corp | 484,010 | 0.87% | $15.60M | +55,757 | 0.00% |
| a16z Capital Management, L.L.C. | 415,000 | 0.75% | $13.38M | – | 0.09% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 115 | 34M | 61.4% | 54 / 27 | 18 / 6 | 3M | 3M |
| Q1 2026 | 69 | 35M | 63.3% | 69 / 0 | 0 / 2 | 35M | 0M |
| Q4 2025 | 2 | 0M | 0.0% | 2 / 0 | 0 / 0 | 0M | 0M |
| Q2 2025 | 0 | 0M | 0.0% | 0 / 0 | 0 / 2 | 0M | 0M |
| Q1 2025 | 2 | 0M | 0.1% | 1 / 0 | 0 / 8 | 0M | 1M |
| Q4 2024 | 9 | 1M | 0.9% | 4 / 1 | 1 / 71 | 0M | 21M |
| Q3 2024 | 78 | 21M | 38.2% | 12 / 10 | 29 / 23 | 4M | 5M |
| Q2 2024 | 91 | 23M | 41.7% | 19 / 20 | 35 / 44 | 5M | 23M |
| Q1 2024 | 117 | 41M | 74.0% | 19 / 41 | 26 / 13 | 14M | 2M |
| Q4 2023 | 111 | 29M | 52.2% | 14 / 30 | 43 / 23 | 3M | 7M |
| Q3 2023 | 120 | 33M | 59.4% | 18 / 33 | 34 / 27 | 5M | 9M |
| Q2 2023 | 131 | 37M | 67.2% | 13 / 47 | 34 / 19 | 4M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
103 funds held AKTS in Q2 2026, 24% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AKTS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 1,462,244 | 2.63% | $32.27M | 0.08% | Jul 31, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 676,577 | 1.22% | $21.81M | 0.23% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 585,135 | 1.05% | $18.86M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 545,302 | 0.98% | $17.58M | 0.02% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 507,000 | 0.91% | $16.34M | 0.91% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 358,947 | 0.65% | $11.57M | 0.23% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 333,745 | 0.60% | $10.76M | 0.09% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 283,355 | 0.51% | $5.88M | 0.11% | May 31, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 266,503 | 0.48% | $5.53M | 0.09% | May 29, 2026 |
| Fidelity Small Cap Index Fund | 232,435 | 0.42% | $5.13M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 209,816 | 0.38% | $6.76M | 0.01% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 196,735 | 0.35% | $6.34M | 0.04% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 163,403 | 0.29% | $5.27M | 0.05% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 133,328 | 0.24% | $4.30M | 0.03% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 105,593 | 0.19% | $2.19M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matthew Roden | President and CEO, Director | 91,998 | 0.17% | Jan 8, 2026 |
| Akos Czibere | Chief Medical Officer | 0 | – | Sep 24, 2026 |
| Shulamit Ron-Bigger | Chief Operating Officer | 34,200 | 0.06% | Jul 10, 2026 |
| Paul L. Feldman | Chief Scientific Officer | 144,568 | 0.26% | Jan 8, 2026 |
| Kyle D. Kuvalanka | Chief Financial Officer | – | – | Jan 8, 2026 |
| Ken Herrmann | Director | 3,506 | 0.01% | Jul 21, 2026 |
| Glenn Gormley | Director | – | – | Apr 16, 2026 |
| Todd Foley | Director, 10% owner | 4,002,533 | 7.20% | Jan 14, 2026 |
| Helen Susan Kim | Director, 10% owner | 5,671,825 | 10.20% | Jan 12, 2026 |
| Oleg Nodelman | Director | 433,527 | 0.78% | Jan 12, 2026 |
| EcoR1 Capital, LLC | Director | – | – | Jan 12, 2026 |
| Lloyd Mitchell Segal | Director | 19,631 | 0.04% | Jan 12, 2026 |
| Michael A. Sherman | Director | – | – | Jan 8, 2026 |
| Mary Thistle | Director | – | – | Jan 8, 2026 |
| LILLY & Co ELI | 10% owner | 6,344,114 | 11.41% | Jan 15, 2026 |
| BioVentures 2018 GP LLC MPM | 10% owner | – | – | Jan 14, 2026 |
| Mpm Bioventures 2018, L.P. | 10% owner | – | – | Jan 14, 2026 |
| BioVentures 2018 LLC MPM | 10% owner | – | – | Jan 14, 2026 |
| Ansbert Gadicke | 10% owner | 7,570,168 | 13.61% | Jan 14, 2026 |
| Asset Management Investors Bv2018 Llc Mpm | 10% owner | – | – | Jan 14, 2026 |
| Oncology Innovations Fund GP LLC MPM | 10% owner | 341,709 | 0.61% | Jan 14, 2026 |
| Oncology Innovations Fund Lp Mpm | 10% owner | 10,260,064 | 18.45% | Jan 14, 2026 |
| Asset Management Llc Mpm | 10% owner | – | – | Jan 14, 2026 |
| Oncology Impact Private Investment Fund 2, L.P. | 10% owner | 341,709 | 0.61% | Jan 14, 2026 |
| Luke Evnin | 10% owner | – | – | Jan 14, 2026 |
| Mpm Bioventures 2018 (B), L.P. | 10% owner | – | – | Jan 14, 2026 |
| Vida Ventures Ii-A, Llc | 10% owner | 5,671,825 | 10.20% | Jan 12, 2026 |
| Vida Ventures II, LLC | 10% owner | – | – | Jan 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Akos Czibere Chief Medical Officer | Sep 23, 2026 | Sale(10b5-1 plan) | −7,401 | $21.03 | $155.64K | 0 |
| Akos Czibere Chief Medical Officer | Sep 23, 2026 | Sale(10b5-1 plan) | −5,099 | $20.19 | $102.95K | 7,401 |
| Akos Czibere Chief Medical Officer | Sep 23, 2026 | Option exercise | +12,500 | $4.95 | $61.88K | 12,500 |
| Ken Herrmann Director | Jul 20, 2026 | Option exercise | +3,506 | $0.08 | $280 | 3,506 |
| Ken Herrmann Director | Jul 20, 2026 | Option exercise | +1,350 | $1.91 | $2.58K | 4,856 |
| Ken Herrmann Director | Jul 20, 2026 | Sale | −3,506 | $24.56 | $86.11K | 1,350 |
| Ken Herrmann Director | Jul 20, 2026 | Sale | −1,350 | $24.56 | $33.16K | 0 |
| Ken Herrmann Director | Jul 17, 2026 | Sale | −3,065 | $25.21 | $77.27K | 0 |
| Ken Herrmann Director | Jul 17, 2026 | Option exercise | +3,065 | $0.08 | $245 | 3,065 |
| Akos Czibere Chief Medical Officer | Jul 8, 2026 | Sale | −4,371 | $28.71 | $125.49K | 0 |
| Akos Czibere Chief Medical Officer | Jul 8, 2026 | Sale | −30,829 | $27.95 | $861.67K | 4,371 |
| Akos Czibere Chief Medical Officer | Jul 8, 2026 | Sale | −14,800 | $27.13 | $401.52K | 35,200 |
| Akos Czibere Chief Medical Officer | Jul 8, 2026 | Option exercise | +50,000 | $4.95 | $247.50K | 50,000 |
| Shulamit Ron-Bigger Chief Operating Officer | Jul 8, 2026 | Sale | −15,800 | $27.13 | $428.65K | 34,200 |
| Shulamit Ron-Bigger Chief Operating Officer | Jul 8, 2026 | Option exercise | +50,000 | $3.66 | $183.00K | 50,000 |
| Shulamit Ron-Bigger Chief Operating Officer | Jul 8, 2026 | Sale | −30,000 | $27.94 | $838.20K | 4,200 |
| Shulamit Ron-Bigger Chief Operating Officer | Jul 8, 2026 | Sale | −4,200 | $28.75 | $120.75K | 0 |
| Todd Foley Director, 10% owner | Jan 12, 2026 | Conversion | +716,872 | – | – | 4,002,533 |
| Todd Foley Director, 10% owner | Jan 12, 2026 | Conversion | +597,391 | – | – | 597,391 |
| Todd Foley Director, 10% owner | Jan 12, 2026 | Buy | +232,870 | $18.00 | $4.19M | 4,235,403 |
| Todd Foley Director, 10% owner | Jan 12, 2026 | Conversion | +2,688,270 | – | – | 3,285,661 |
| Ansbert Gadicke 10% owner | Jan 12, 2026 | Conversion | +5,914,197 | – | – | 7,570,168 |
| Ansbert Gadicke 10% owner | Jan 12, 2026 | Conversion | +1,577,119 | – | – | 9,147,287 |
| Ansbert Gadicke 10% owner | Jan 12, 2026 | Buy | +1,112,777 | $18.00 | $20.03M | 10,260,064 |
| Ansbert Gadicke 10% owner | Jan 12, 2026 | Conversion | +1,314,262 | – | – | 1,655,971 |
| Oncology Innovations Fund Lp Mpm 10% owner | Jan 12, 2026 | Buy | +1,112,777 | $18.00 | $20.03M | 10,260,064 |
| Oncology Innovations Fund Lp Mpm 10% owner | Jan 12, 2026 | Conversion | +1,314,262 | – | – | 1,655,971 |
| Oncology Innovations Fund Lp Mpm 10% owner | Jan 12, 2026 | Conversion | +5,914,197 | – | – | 7,570,168 |
| Oncology Innovations Fund Lp Mpm 10% owner | Jan 12, 2026 | Conversion | +1,577,119 | – | – | 9,147,287 |
| Helen Susan Kim Director, 10% owner | Jan 12, 2026 | Buy | +812,455 | $18.00 | $14.62M | 5,671,825 |
| Helen Susan Kim Director, 10% owner | Jan 12, 2026 | Conversion | +134,842 | – | – | 134,842 |
| Helen Susan Kim Director, 10% owner | Jan 12, 2026 | Buy | +22,545 | $18.00 | $405.81K | 157,387 |
| Helen Susan Kim Director, 10% owner | Jan 12, 2026 | Conversion | +4,859,370 | – | – | 4,859,370 |
| Lloyd Mitchell Segal Director | Jan 12, 2026 | Conversion | +19,631 | – | – | 19,631 |
| Oleg Nodelman Director | Jan 12, 2026 | Buy | +144,443 | $18.00 | $2.60M | 347,305 |
| Oleg Nodelman Director | Jan 12, 2026 | Conversion | +2,270,879 | – | – | 2,270,879 |
| Oleg Nodelman Director | Jan 12, 2026 | Conversion | +202,862 | – | – | 202,862 |
| Oleg Nodelman Director | Jan 12, 2026 | Conversion | +128,506 | – | – | 128,506 |
| Oleg Nodelman Director | Jan 12, 2026 | Buy | +2,077,779 | $18.00 | $37.40M | 4,348,658 |
| Vida Ventures Ii-A, Llc 10% owner | Jan 12, 2026 | Buy | +812,455 | $18.00 | $14.62M | 5,671,825 |
| Vida Ventures Ii-A, Llc 10% owner | Jan 12, 2026 | Conversion | +134,842 | – | – | 134,842 |
| Vida Ventures Ii-A, Llc 10% owner | Jan 12, 2026 | Buy | +22,545 | $18.00 | $405.81K | 157,387 |
| Vida Ventures Ii-A, Llc 10% owner | Jan 12, 2026 | Conversion | +4,859,370 | – | – | 4,859,370 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aktis Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 28,211 shares on Oct 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Akos Czibere Officer | Sep 23, 2026 | 25,000 | $552.75K | Sep 23, 2026 | Exercise of Stock Options |
| Ken Herrmann Director | Jul 20, 2026 | 4,856 | $119.27K | Jul 20, 2026 | Stock Option Exercise |
| Ken Herrmann Director | Jul 17, 2026 | 3,065 | $77.26K | Jul 17, 2026 | Stock Option Exercise |
| Akos Czibere Officer | Jul 8, 2026 | 50,000 | $1.39M | Jul 8, 2026 | Exercise of Options Under a Registered Plan |
| Shulamit Ron-Bigger Officer | Jul 8, 2026 | 50,000 | $1.39M | Jul 8, 2026 | Exercise of Options Under a Registered Plan |
See a number that looks wrong?